Highly stable sialic acid solution and use thereof

Abstract

The present application relates to the technical field of food nutrition fortifier, and particularly provides a high-stability sialic acid solution and application thereof. It is found for the first time that the mass ratio of sialic acid to divalent iron ions in the sialic acid solution is 1:(1-2), which can effectively improve the stability of sialic acid in the sialic acid aqueous solution, reduce the decay rate of sialic acid, and the sialic acid solution has no browning. Furthermore, it is also found that the divalent iron ions added in the sialic acid solution can be stabilized in the divalent iron state which is easy to be absorbed by the human body.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of food nutrition fortifier, and specifically provides a high-stability sialic acid solution and application thereof. BACKGROUND

[0002] Iron is one of the essential trace elements for organisms, and as the most abundant trace element, it plays a very important role in maintaining normal metabolism and growth and development of organisms. The physiological functions of iron in the body include participating in oxygen transport and electron transfer processes in the body, maintaining normal hematopoietic function in the body, and enhancing immune function of the body, etc. In addition, since iron is a transition metal, it can be converted between different valence states, and is an important cofactor for many heme proteins and non-heme iron-containing proteins to exert physiological functions.

[0003] In current iron supplements, inorganic iron salts have problems of low bioavailability and gastrointestinal discomfort; amino acid chelated iron has a high cost, and excessive intake can affect the absorption of other amino acids by the human body. In the prior art, iron supplements are often combined with vitamin C to improve iron absorption, the main principle of which is that vitamin C can reduce the trivalent iron that is difficult to absorb into divalent iron that is easy to absorb, thereby promoting the absorption of iron. In addition, it can also keep the thiol group of ferrochelatase and other enzymes in an active state so as to effectively exert the function.

[0004] Sialic acid (N-acetylneuraminic acid) is a nine-carbon monosaccharide, which exists in various forms in many organisms, and the content of N-acetylneuraminic acid and its derivative types in organisms also increase with the increase of biological evolution. N-acetylneuraminic acid in mammals is mainly present in cerebrospinal fluid and mucus. N-acetylneuraminic acid is a neuraminic acid, which is an important component of cell membrane protein and participates in various physiological functions on the cell surface, plays a very important role in regulating physiological and biochemical functions of the human body, can promote the development of the nervous system of infants, fetuses and children, improve memory and intelligence level, slow down brain cell aging, slow down memory decline, prevent senile dementia, and has the effects of anti-virus, anti-tumor, inhibition of leukocyte adhesion and anti-inflammatory, and improvement of human immunity. Sialic acid has a wide range of applications, and is often used in the form of aqueous solution in the fields of food and cosmetics. The sialic acid aqueous solution is colorless and transparent, but the sialic acid aqueous solution is unstable, and with the extension of time, the color of the aqueous solution will gradually change from colorless to light yellow, and then gradually deepen, which seriously affects the application of sialic acid.

[0005] In the previous research, the applicant found that the combination of sialic acid and ferrous drugs for iron supplementation can promote the absorption of ferrous iron and improve the bioavailability of iron. SUMMARY

[0006] In the prior art, sialic acid will attenuate during storage, and the aqueous solution of SA will change color. In previous studies, the stability of sialic acid aqueous solution is improved by changing the pH of the sialic acid aqueous solution.

[0007] In the present application, the applicant accidentally found that the addition of divalent iron can reduce the attenuation rate of sialic acid and increase the stability of sialic acid aqueous solution in the follow-up study of the efficacy of sialic acid and ferrous drugs.

[0008] In the first aspect, the present application provides the application of high-stability sialic acid solution in reducing the attenuation rate of divalent iron ions and sialic acid; the mass ratio of sialic acid to divalent iron ions in the high-stability sialic acid solution is 1:(1-2).

[0009] Furthermore, the present application confirms that SA and ferrous solution have excellent stability at a certain concentration ratio. In the stability investigation, the attenuation amplitude of SA is high, and a large amount of ferrous ions is oxidized to ferric ions when the concentration ratio exceeds this range.

[0010] In the application of high-stability sialic acid solution provided by the present application in reducing the attenuation rate of divalent iron ions and sialic acid, the concentration of sialic acid is less than or equal to 50 mg / 100 mL.

[0011] In the application of high-stability sialic acid solution provided by the present application in reducing the attenuation rate of divalent iron ions and sialic acid, the concentration of divalent iron ions is 50-100 mg / 100 mL.

[0012] In the application provided by the present application, the divalent iron ions are ferrous citrate.

[0013] In the second aspect, the present application provides a high-stability sialic acid solution, and the mass ratio of sialic acid to divalent iron ions in the high-stability sialic acid solution is 1:(1-2); the divalent iron ions are ferrous citrate.

[0014] In the third aspect, the present application further provides a preparation method of high-stability sialic acid solution, which comprises mixing sialic acid and ferrous citrate in water and sterilizing to obtain the high-stability sialic acid solution.

[0015] In the fourth aspect, the present application provides a method for improving the stability of sialic acid solution, which comprises adding divalent iron ions to the sialic acid solution so that the mass ratio of sialic acid to divalent iron ions in the sialic acid solution is 1:(1-2).

[0016] In the method for improving the stability of sialic acid solution provided by the present application, the divalent iron ions are ferrous citrate.

[0017] The present application also claims the application of the high-stability sialic acid solution in preparing iron supplements.

[0018] In a fifth aspect, the present application provides an iron supplement, wherein the mass ratio of sialic acid to divalent iron ion is 1:(1-2); and the divalent iron ion is ferrous citrate.

[0019] In the present application, the ferrous citrate can be selected from ferrous citrate, sodium ferrous citrate, potassium ferrous citrate, without limitation on the type of salt under the premise of ensuring absorption efficiency.

[0020] The present application has the following beneficial effects:

[0021] The present application first proposes that the mass ratio of sialic acid to divalent iron ion in the sialic acid solution is 1:(1-2), which can effectively improve the stability of sialic acid in the sialic acid aqueous solution and reduce the decay rate of sialic acid. Moreover, it is found that the divalent iron ion added in the sialic acid solution is basically not oxidized and can remain in the divalent iron state which is easy to be absorbed by the human body. DETAILED DESCRIPTION

[0022] To make the objectives, technical solutions and advantages of the present application clearer, the technical solutions in the present application will be described clearly and completely below. Obviously, the described embodiments are some of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of protection of the present application.

[0023] The sialic acid used in the present application is conventional sialic acid. In the embodiments of the present application, the sialic acid used is sialic acid obtained by the extraction method disclosed in CN201811372637.8. All the solutions disclosed in CN201811372637.8 are included in the present application.

[0024] Embodiment 1

[0025] The experimental samples used in this embodiment are sialic acid, sodium ferrous citrate and ferrous sulfate. The experimental steps are as follows:

[0026] (1) Prepare sialic acid aqueous solutions with different amounts of sialic acid added, sodium ferrous citrate aqueous solutions, ferrous sulfate aqueous solutions, sialic acid + sodium ferrous citrate aqueous solutions and sialic acid + ferrous sulfate aqueous solutions, and measure the initial content. The results are shown in Table 1.

[0027] Table 1 Preparation concentration of different sialic acid aqueous solutions and sialic acid + sodium ferrous citrate aqueous solutions

[0028] Concentration of the preparation Treatment group 1 SA 50 mg / 100 ml; sodium ferrous citrate 50 mg / 100 ml Treatment group 2 SA 50 mg / 100 ml; sodium ferrous citrate 100 mg / 100 ml Treatment group 3 SA 25 mg / 100 ml; sodium ferrous citrate 50 mg / 100 ml Treatment group 4 SA 50 mg / 100 ml Treatment group 5 SA 100 mg / 100 ml Treatment group 6 SA 100 mg / 100 ml; sodium ferrous citrate 50 mg / 100 ml Treatment group 7 SA 100 mg / 100 ml; sodium ferrous citrate 100 mg / 100 ml Treatment group 8 SA 50 mg / 100 ml; sodium ferrous citrate 25 mg / 100 ml Treatment group 9 SA 50 mg / 100 ml; sodium ferrous citrate 150 mg / 100 ml Treatment group 10 Sodium ferrous citrate 50 mg / 100 ml Treatment group 11 Sodium ferrous citrate 100 mg / 100 ml Treatment group 12 Ferrous sulfate 50 mg / 100 ml Treatment group 13 Ferrous sulfate 100 mg / 100 ml Treatment group 14 SA 50 mg / 100 ml; ferrous sulfate 50 mg / 100 ml Treatment group 15 SA 50 mg / 100 ml; ferrous sulfate 100 mg / 100 ml Treatment group 16 SA 25 mg / 100 ml; ferrous sulfate 50 mg / 100 ml

[0029] (2) UHT sterilization of the solution in (1), observe the color of the solution after sterilization and measure the content. Except for the treatment groups 4 and 5 which are colorless, the other groups are all light green transparent liquid of ferrous ions, sampling inspection group 4 / 5, 10 / 11 sialic acid and ferrous ion content, the difference with the initial content is within ± 0.3% and ± 0.1%, it can be considered that the UHT heating has no effect on the content of sialic acid and ferrous ion.

[0030] (3) The sterilized solution in (2) is stored at 45°C for one month, the color change is observed and the content is tested, the results are shown in Table 2.

[0031] Table 2 Color of the solution and SA and ferrous ion attenuation rate of the solution after accelerated storage at 45°C for one month

[0032] SA decay Solution color sensory Ferrous ion decay Presence of precipitate Treatment group 1 0.71％ Green 1.53％ No Treatment group 2 0.80％ Green 1.14％ No Treatment group 3 0.62％ Green 1.07％ No Treatment group 4 3.44％ Brown - No Treatment group 5 6.85％ Brownish - Yes Treatment group 6 12.27％ Brown 7.04％ Yes Treatment group 7 8.94％ Brown 6.74％ Yes Treatment group 8 4.32％ Brownish 7.05％ Yes Treatment group 9 1.56％ Brown 6.09％ No Treatment group 10 - Yellow-green 4.03％ No Treatment group 11 - Yellow-green 4.62％ No Treatment group 12 - Yellow-green 4.55％ No Treatment group 13 - Yellow-green 5.79％ No Treatment group 14 3.73％ Brown 3.95％ No Treatment group 15 3.66％ Brown 5.05％ No Treatment group 16 3.37％ Yellow 3.71％ No

[0033] Note: In the present application, the order of brown color from light to dark is brown < brownish < brown, and the order of yellow-green color from light to dark is green < greenish yellow < yellow-green < yellow.

[0034] (4) Change the sterilization method of the solution in (1), steam sterilization at 110°C for 20 min.

[0035] (5) The sterilized solution in (4) is stored at 45°C for one month, the color change is observed and the content is tested, the results are shown in Table 3.

[0036] Table 3 Color of the solution and SA and ferrous ion attenuation rate of the solution after accelerated storage at 45°C for one month

[0037]

[0038]

[0039] Note: In the present application, the order of brown color from light to dark is brown < brownish < brown, and the order of yellow-green color from light to dark is green < greenish yellow < yellow-green < yellow.

[0040] (6) Determine the optimal amount of sialic acid + ferrous sodium citrate added to the solution.

[0041] From the results of Table 2 and Table 3, when the mass ratio of sialic acid to divalent iron ions in the sialic acid solution is 1:(1-2), the attenuation rates of sialic acid and divalent iron ions in the sialic acid solution are both low.

[0042] In addition, from Table 3, although just after sterilization, there is little difference between the ferrous sodium citrate group and the ferrous sulfate group, but after accelerated testing, the stability of the ferrous sodium citrate group is significantly stronger than that of the ferrous sulfate group.

[0043] Finally, it should be noted that the above examples are only used to illustrate the technical solutions of the present application, and are not intended to limit the same; although the present application has been described in detail with reference to the foregoing examples, those of ordinary skill in the art should understand that they can still modify the technical solutions recorded in the foregoing examples, or make equivalent replacements for some of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. A method for improving the stability of a sialic acid solution, characterized by, adding divalent iron ion into the sialic acid solution, so that the mass ratio of sialic acid to divalent iron ion in the sialic acid solution is 1:(1-2); the concentration of sialic acid in the high-stability sialic acid solution is less than or equal to 50 mg / 100 mL; the concentration of divalent iron ion in the high-stability sialic acid solution is 50-100 mg / 100 mL; the divalent iron ion is ferrous citrate.

2. A high stability sialic acid solution characterized in that, the mass ratio of sialic acid to divalent iron ion in the high-stability sialic acid solution is 1:(1-2); the concentration of sialic acid in the high-stability sialic acid solution is less than or equal to 50 mg / 100 mL; the concentration of divalent iron ion in the high-stability sialic acid solution is 50-100 mg / 100 mL; the divalent iron ion is ferrous citrate.

3. The method of producing a high stability sialic acid solution according to claim 2, characterized by, mixing sialic acid and ferrous citrate in water, and sterilizing to obtain the high-stability sialic acid solution.

4. Use of the high-stability sialic acid solution of claim 2 in the preparation of iron supplement.

5. An iron supplement, characterized in that, made from the high-stability sialic acid solution of claim 2.

Images